Business Overview: Cue Biopharma, Inc. (Nasdaq: CUE)

---

Executive Summary

Cue Biopharma is a clinical-stage biopharmaceutical company that has spent most of its public life developing precision T-cell immunotherapies through its proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform, originally aimed at oncology (CUE-101, CUE-102) and, more recently, autoimmune disease (CUE-401, CUE-501). Like most pre-commercial biotechs, the company has never generated product revenue and has historically carried explicit "going concern" language in its SEC filings, reflecting a business that depends entirely on partnership payments, equity issuance, and debt to fund a persistent cash burn.

2025 and 2026 have been transformational — and highly dilutive — years for the company. Facing a genuine capital crisis, Cue (1) monetized its legacy oncology franchise through a 2025 collaboration and license agreement with ImmunoScape (a $15 million upfront deal plus a 40% equity stake in ImmunoScape), (2) brought in a new leadership team (President/CEO Usman Azam in September 2025, later succeeded in the CEO role by Dr. Shao-Lee Lin, plus a new CMO and CFO), (3) executed a 1-for-30 reverse stock split in April 2026 to regain Nasdaq compliance, and (4) pivoted the pipeline decisively toward immunology/allergy by in-licensing Ascendant-221 (renamed CUE-221), a clinical-stage anti-IgE antibody, from Ascendant Health Sciences for a $15 million upfront payment plus up to $676.5 million in potential milestones. The Ascendant deal and associated financing activity triggered enormous non-cash GAAP charges (a $153.1 million net loss in Q2 2026 alone, driven by a $63.1 million non-cash loss on the license agreement and ~$20 million of non-cash warrant fair-value charges) that make reported earnings nearly impossible to interpret without adjustment.

The single most decision-relevant fact for investors is that Cue Biopharma today is best understood as an entirely different company than it was two years ago: a shell of legacy T-cell oncology assets (now largely monetized or partnered away) wrapped around a newly in-licensed, later-stage immunology/allergy pipeline (CUE-221 for chronic spontaneous urticaria and food allergy, CUE-401 for autoimmune disease) funded by a series of highly dilutive raises — most recently a $50 million private placement completed after quarter-end that brought pro forma cash to roughly $67.4 million against a share count reset by the 2026 reverse split. Near-term catalysts (CUE-221 Phase 2 CSU data expected by the end of Q3 2026 and CUE-401's IND/Phase 1 initiation targeted for year-end 2026) will determine whether this pivot restores a viable, fundable business or merely delays an unresolved going-concern problem.

---

1. Core Business Model & How They Work

Cue Biopharma does not sell products; it generates value (and occasional cash) through a combination of collaboration/licensing revenue and continual capital raises used to fund pipeline development, with the goal of eventually advancing a candidate to approval or a lucrative partnership/M&A outcome. Historically, the company's model centered on its Immuno-STAT platform — engineered biologics designed to selectively engage disease-relevant T cells by combining TCR-targeting domains with co-stimulatory signals, aiming to modulate immune responses precisely rather than broadly (as checkpoint inhibitors do). That oncology-focused model produced encouraging but early clinical data (CUE-101 monotherapy and CUE-101 + pembrolizumab combination data in HPV+ head and neck cancer) but never reached a self-funding scale, and the company's cash position deteriorated to the point of recurring going-concern disclosures.

Beginning in late 2025, management shifted the model decisively: rather than continue funding oncology programs organically, Cue monetized/partnered its legacy T-cell oncology IP (the ImmunoScape collaboration) and used the resulting capital and new leadership to in-license a later-stage, de-risked immunology/allergy asset (CUE-221) from a third party, alongside continuing to advance its wholly-owned CUE-401 autoimmune program. This is effectively a "platform-to-portfolio" pivot — trading a single proprietary technology platform for a more diversified, licensed pipeline in indications (chronic spontaneous urticaria, food allergy, autoimmune disease) viewed as having clearer regulatory and commercial paths than oncology combination therapy.

Key Operational Drivers

1. In-Licensed, Later-Stage Pipeline (CUE-221) — global rights (ex-Greater China) to Ascendant-221, a Phase 2 dual-mechanism anti-IgE antibody, acquired for $15 million upfront plus up to $676.5 million in milestones, with Phase 2 chronic spontaneous urticaria data expected by the end of Q3 2026.
2. Wholly-Owned Autoimmune Asset (CUE-401) — a Treg-mediated tolerance-inducing bifunctional molecule targeting autoimmune/inflammatory disease, with IND submission and Phase 1 initiation targeted for year-end 2026.
3. Legacy Oncology Monetization — the ImmunoScape collaboration (T-cell therapy for solid tumors) converted CUE's original Immuno-STAT oncology franchise into upfront cash ($15 million total) and a 40% equity stake in ImmunoScape, plus continuing milestone-linked revenue (e.g., a Boehringer Ingelheim milestone recognized in Q2 2026).
4. Serial Equity Financing Under Distress — a 1-for-30 reverse split (April 2026), a $30 million gross PIPE alongside the Ascendant license, and a subsequent $50 million private placement illustrate a financing pattern driven by necessity rather than strength, with substantial dilution to existing holders.
5. New Leadership Team — a wholesale leadership refresh (new CEO, CMO, and CFO through 2025–2026) tasked with executing the immunology/allergy pivot and restoring investor confidence after years of going-concern risk.

---

2. Business Segments

Cue Biopharma operates as a single operating segment (clinical-stage biopharmaceutical R&D); it has no commercial product sales and does not report discrete business segments. Its activities are better understood as a portfolio of pipeline programs at different stages and under different economic structures (wholly owned, out-licensed, or in-licensed) rather than as formal reporting segments.

---

3. Product Portfolio

---

4. Competitive Landscape

Cue Biopharma now competes across two very different fronts. In immunology/allergy (CUE-221, CUE-401), it faces large, well-capitalized pharmaceutical companies with approved or late-stage anti-IgE and biologic therapies for urticaria, food allergy, and autoimmune indications, where clinical differentiation, manufacturing scale, and commercial infrastructure matter enormously. In its legacy T-cell oncology work (now largely conducted through the ImmunoScape collaboration), it competes against numerous better-funded cell-therapy and immuno-oncology developers. In both cases, Cue's own filings acknowledge that competitors possess "greater financial, technical and human resources," and as a company with a market capitalization in the low hundreds of millions and a history of going-concern risk, Cue has essentially no scale advantage against any of them — its competitive proposition rests entirely on the strength of specific clinical assets and speed to key data readouts.

Key Competitors:

• Amgen, Bristol-Myers Squibb, Merck, and Nektar Therapeutics (broad immuno-oncology and immunology competitors named in its filings)
• Established and pipeline anti-IgE / allergy biologics developers competing directly with CUE-221 in chronic spontaneous urticaria and food allergy
• Numerous well-funded autoimmune/inflammatory disease biotechs and large pharma immunology franchises competing with CUE-401
• Cell-therapy and T-cell receptor discovery companies competing with the ImmunoScape-partnered oncology assets

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• A later-stage, externally validated asset (CUE-221) with existing Phase 1 human safety data and an imminent Phase 2 CSU readout, reducing near-term clinical risk relative to a purely internally-generated pipeline.
• Meaningful near-term non-dilutive-adjacent value creation through the ImmunoScape collaboration (upfront cash, a 40% equity stake, and milestone-linked revenue such as the Q2 2026 Boehringer Ingelheim milestone) that helps offset the cost of the immunology pivot.
• A refreshed leadership team with allergy/immunology-specific expertise (new CMO with allergic/autoimmune disease background) better aligned with the company's new strategic direction than its prior oncology-focused organization.
• Improved (though still thin) near-term liquidity following the post-quarter $50 million private placement, which brought pro forma cash to roughly $67.4 million.

Strategic Risks & Vulnerabilities

1. Extreme and recurring shareholder dilution — share count expansion from roughly 61.8 million (FY2024) to 97.7 million pre-split, a 1-for-30 reverse split in April 2026, and multiple subsequent warrant- and PIPE-driven raises have repeatedly diluted existing holders and are likely to continue given the company's persistent cash needs.
2. Going-concern history and dependency on continuous financing — Cue's SEC filings have repeatedly disclosed "substantial doubt" about its ability to continue as a going concern, and even large raises (the April 2026 PIPE, the August 2026 $50 million placement) have historically been described as insufficient on their own to resolve that doubt.
3. Execution risk on a newly in-licensed, unproven-to-Cue asset — CUE-221 was licensed from Ascendant Health Sciences only in 2026; Cue has limited internal experience with the program, and Phase 2 CSU and food-allergy data are still pending, with no efficacy readout yet in hand.
4. Opaque, non-cash-charge-dominated financial statements — GAAP net losses (e.g., $153.1 million in Q2 2026 alone) are now driven primarily by non-cash warrant fair-value and license-related accounting charges, making it difficult for investors to assess underlying cash burn and true runway without careful adjustment.

---

6. Financial Overview

---

7. Summary Conclusion

Cue Biopharma has undergone one of the more dramatic strategic transformations among small-cap clinical-stage biotechs over the past 18 months: from a going-concern-flagged, single-platform oncology immunotherapy developer to a newly capitalized immunology/allergy company built around an in-licensed, later-stage anti-IgE antibody (CUE-221) and a wholly-owned autoimmune candidate (CUE-401), funded by monetizing its legacy oncology IP through the ImmunoScape collaboration and by absorbing enormous share dilution, including an April 2026 reverse split and successive PIPE-style raises. The strategy has bought the company real, near-term catalysts — CUE-221 Phase 2 CSU data by the end of Q3 2026 and a CUE-401 IND/Phase 1 start targeted for year-end 2026 — and roughly $67 million of pro forma cash following the August 2026 raise. But the underlying risk profile has not fundamentally changed: Cue remains a pre-revenue, serially dilutive biotech with a documented going-concern history, now making a high-stakes bet that in-licensed, later-stage immunology assets can succeed where its own internally developed oncology platform could not. Investors should treat CUE as a binary, catalyst-driven speculative holding rather than a stable operating business, with the CUE-221 Phase 2 readout as the most immediate value-defining event.